Investing.com -- Wells Fargo has released its Q2 2025 Tactical Ideas list on Tuesday, highlighting 10 stocks across nine subsectors that analysts believe could see significant catalysts in the coming quarter. 

The list includes Eli Lilly (NYSE:LLY) and Roku (NASDAQ:ROKU) among other high-conviction ideas, according to Wells Fargo.

Eli Lilly made the list due to the company's orforglipron diabetes drug, which analysts expect to show an Ozempic-like profile in its Q2 readout. 

"We see a high probability of success for the orforglipron diabetes readout in 2Q25, with 5-10% upside on this outcome," said Wells Fargo.

Roku was also featured, as analysts believe concerns over a revenue slowdown are overblown. 

"We think recent fears about a material revenue growth slowdown are overdone, and Roku should maintain its '25 guidance of +mid-teens% Platform rev growth," Wells Fargo stated.

Other Overweight-rated stocks on the list include Check Point Software (NASDAQ:CHKP), Capital One Financial (NYSE:COF), Capri Holdings (NYSE:CPRI), Dollar Tree (NASDAQ:DLTR), KKR & Co (NYSE:KKR)., PTC Therapeutics (NASDAQ:PTCT), and Rhythm Pharmaceuticals (NASDAQ:RYTM). 

Analysts highlighted potential earnings beats, regulatory approvals, and strategic moves as key drivers for these stocks.

The bank’s Tactical Ideas list is updated quarterly, with stocks chosen based on their potential for meaningful upside or downside in the coming months, according to Wells Fargo. 

With Eli Lilly and Roku among the selections, analysts see strong catalysts ahead for both companies in Q2 2025.

Related articles

Jefferies maintains hold on NextEra Energy, target at $77

Outset Medical stock hits 52-week low at $0.43 amid market challenges

The Ritz-Carlton Debuts in Suzhou, Showcasing the Timeless Elegance and Rich Heritage of China's Venice of the East